Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 498Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
ETHICS EDUCATION
Year : 2020  |  Volume : 11  |  Issue : 4  |  Page : 174-177

Consent concerns in clinical trials of investigational therapies for COVID-19: Vulnerability versus voluntariness


Consultant – Clinical Research and Drug Development, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Arun Bhatt
303-4, Dheeraj Valley 3/C, Mohan Gokhale Road, Goregaon East, Mumbai - 400 063, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/picr.PICR_271_20

Rights and Permissions

Obtaining informed consent from vulnerable patients participating in clinical trials of investigational therapies for COVID-19 is a major ethical challenge. Ethical and operational considerations – voluntariness, waiver, timing, time, documentation, and responsibilities of the sponsor, the investigator, and the ethics committee – are discussed briefly.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed352    
    Printed12    
    Emailed0    
    PDF Downloaded48    
    Comments [Add]    

Recommend this journal